During the pandemic, according to the ESMO recommendations, cytostatic treatment could be applied to non-disabled patients with the allowance of G-CSF primary prevention in patients with multiple risk factors for developing neutropenia during CTH regimens with intermediate risk of FN [35]. The gene discussed is CSF3; the disease is neutropenia.